Fiasp (fast-acting insulin aspart) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 7 Diseases   10 Trials   10 Trials   866 News 


123456789»
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Journal:  Comparing Postprandial Glycemic Control using Fiasp vs. Insulin Aspart in Hospitalized Patients with Type 2 Diabetes. (Pubmed Central) -  Dec 7, 2024   
    Faster insulin formulation with AID improved postprandial glycaemic outcomes and could be a useful therapeutical option in youth with type 1 diabetes that have challenges achieving glycaemic targets. Fiasp provides non-inferior postprandial glucose control in hospitalized patients with type 2 diabetes when compared to Novolog with no increase in rates of hypoglycemia.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion, Enrollment change:  CONNECT 1: A Research Study Looking at How the Use of NovoPen (clinicaltrials.gov) -  Oct 1, 2024   
    P=N/A,  N=411, Completed, 
    The use of Fiasp and Lyumjev during Boost or Ease-off resulted in comparable safety and efficacy to using insulin aspart and lispro. Enrolling by invitation --> Completed | N=227 --> 411
  • ||||||||||  Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Tresiba (insulin degludec) / Novo Nordisk, Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Journal, Real-world evidence, Real-world:  Nocturnal Glucose Profile According to Timing of Dinner Rapid Insulin and Basal and Rapid Insulin Type: An Insulclock (Pubmed Central) -  Jul 27, 2024   
    Mealtime URAI improves 1- and 2-hour postprandial glycemic control compared to RAI without increasing hypoglycemia or weight gain. The dinner rapid insulin timing, insulin type, and the use of correction injections affect the nocturnal glucose profile in T1D.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, Lyumjev (insulin lispro-aabc injection) / Eli Lilly
    Journal:  Postprandial Glucose Excursions with Ultra-Rapid Insulin Analogues in Hybrid Closed-Loop Therapy for Adults with Type 1 Diabetes. (Pubmed Central) -  Jul 15, 2024   
    P=N/A
    In contrast, there were no significant differences in iAUC-2h, iAUC-4h, and the other measures of postprandial glucose control between insulin aspart and Fiasp during breakfast, lunch, and evening meal (p>0.05). Conclusion The use of Lyumjev with CamAPS FX closed-loop system improved postprandial glucose excursions compared with insulin lispro, while the use of Fiasp did not provide any advantage compared with insulin aspart.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion:  Evaluation of the MiniMed (clinicaltrials.gov) -  Jun 26, 2024   
    P=N/A,  N=240, Completed, 
    Conclusion The use of Lyumjev with CamAPS FX closed-loop system improved postprandial glucose excursions compared with insulin lispro, while the use of Fiasp did not provide any advantage compared with insulin aspart. Active, not recruiting --> Completed
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, Lyumjev (insulin lispro-aabc injection) / Eli Lilly
    Glycemic Outcomes with Rapid Insulin vs. Ultrarapid Insulin in Omnipod 5 (OP5) (Poster Hall (West A4-B2); 828) -  May 20, 2024 - Abstract #ADA2024ADA_1869;    
    However, satisfaction and bolus overrides improved with ultrarapid insulin. A larger sample size and meal-specific measures are needed to connect patient experience with glycemic outcomes.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Use of Faster Aspart in Pregnancy (Poster Hall (West A4-B2); 1877) -  May 20, 2024 - Abstract #ADA2024ADA_1525;    
    The MAGE analysis revealed that women in the faster aspart group had significantly lower glycemic variability (fluctuations) at all three mealtimes compared to those in the insulin aspart group. The birth weight, respiratory rate, and pulse rate of the neonates born to mothers on insulin aspart were significantly higher compared to those born to mothers on faster aspart
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, Afrezza (recombinant human insulin inhalation) / MannKind, Apidra (insulin glulisine) / Sanofi
    Review, Journal:  Prandial Insulins: A Person-Centered Choice. (Pubmed Central) -  May 9, 2024   
    The Technosphere insulin offers an inhaled route for prandial insulin delivery...Ongoing research is focused on refining prandial insulin replacement and exploring newer delivery methods. The article provides a comprehensive overview of various prandial insulin options and their clinical applications in the management of diabetes.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial primary completion date, Real-world evidence, Real-world:  CONNECT 1: A Research Study Looking at How the Use of NovoPen (clinicaltrials.gov) -  Mar 29, 2024   
    P=N/A,  N=227, Enrolling by invitation, 
    Black and Latino enrollees also index higher for use of Novolog/Fiasp (insu- lin aspart)...Latino people Trial primary completion date: Mar 2024 --> Sep 2024
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Enrollment closed:  Evaluation of the MiniMed (clinicaltrials.gov) -  Mar 11, 2024   
    P=N/A,  N=240, Active, not recruiting, 
    Trial primary completion date: Mar 2024 --> Sep 2024 Recruiting --> Active, not recruiting
  • ||||||||||  Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Tresiba (insulin degludec) / Novo Nordisk, Fiasp (fast-acting insulin aspart) / Novo Nordisk
    NOCTURNAL GLUCOSE PROFILE IS RELATED TO PRE?DINNER RAPID INSULIN INJECTION TIMING AND TYPE () -  Mar 6, 2024 - Abstract #ATTD2024ATTD_1079;    
    Recruiting --> Active, not recruiting The timing and type of dinner prandial insulin injection affects the entire nocturnal glucose profile.
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Enrollment closed, Trial primary completion date, Combination therapy:  Afrezza (clinicaltrials.gov) -  Mar 5, 2024   
    P3,  N=319, Active, not recruiting, 
    The timing and type of dinner prandial insulin injection affects the entire nocturnal glucose profile. Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2024 --> Sep 2024
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes (clinicaltrials.gov) -  Feb 25, 2024   
    P1,  N=23, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2024 --> Sep 2024 Recruiting --> Completed | N=40 --> 23 | Trial completion date: Jan 2024 --> Apr 2023 | Trial primary completion date: Jan 2024 --> Apr 2023
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Trial completion date, Combination therapy:  Afrezza (clinicaltrials.gov) -  Jan 5, 2024   
    P3,  N=264, Recruiting, 
    The use of URLi with CamAPS FX closed?loop system improved postprandial glucose control compared with insulin lispro. Trial completion date: Apr 2024 --> Apr 2025
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion date, Trial primary completion date:  Evaluation of the MiniMed (clinicaltrials.gov) -  Dec 31, 2023   
    P=N/A,  N=250, Recruiting, 
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
    Trial completion, Trial completion date, Trial primary completion date:  Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) -  Dec 26, 2023   
    P3,  N=139, Completed, 
    Trial completion date: Apr 2024 --> Apr 2025 Recruiting --> Completed | Trial completion date: Dec 2023 --> May 2023 | Trial primary completion date: Dec 2023 --> May 2023
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Review, Journal:  The Role of Ultra-Rapid-Acting Insulin Analogs in Diabetes: An Expert Consensus. (Pubmed Central) -  Nov 8, 2023   
    Unfortunately, there are only few available recommendations from authoritative sources for use of URAA in clinical practice. Therefore, this expert consensus report aims to define populations of people with diabetes mellitus for whom URAA may be beneficial and to provide health care professionals with concrete, practical recommendations on how best to use URAA in this context.
  • ||||||||||  Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Tresiba (insulin degludec) / Novo Nordisk, Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Review, Journal:  New Insulins for Type 1 Diabetes treatment (Pubmed Central) -  Nov 4, 2023   
    New technologies under development include biosimilar insulins such as the glargine biosimilar, already available in the clinic. New formulations are being developed for the future, as well as novel ways of dispersing them, mimicking the action of pancreatic cells, which will allow a more physiological and personalized management of the disease.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion date, Trial primary completion date:  Evaluation of the MiniMed (clinicaltrials.gov) -  Oct 26, 2023   
    P=N/A,  N=250, Recruiting, 
    Faster aspart can be used in women with type 1 or type 2 diabetes during pregnancy and post-delivery with no additional safety issues. Trial completion date: Feb 2024 --> May 2024 | Trial primary completion date: Feb 2024 --> May 2024
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion date, Real-world evidence, Real-world:  CONNECT 1: A Research Study Looking at How the Use of NovoPen (clinicaltrials.gov) -  Sep 21, 2023   
    P=N/A,  N=227, Enrolling by invitation, 
    Active, not recruiting --> Completed Trial completion date: Mar 2024 --> Sep 2024
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Trial primary completion date, Combination therapy:  Afrezza (clinicaltrials.gov) -  Sep 13, 2023   
    P3,  N=264, Recruiting, 
    Trial completion date: Mar 2024 --> Sep 2024 Trial primary completion date: Aug 2023 --> Dec 2023
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion, Trial completion date, Trial primary completion date:  Comparison of FiAsp and Aspart During Postprandial Exercise in Adults With Type 1 Diabetes (clinicaltrials.gov) -  Sep 1, 2023   
    P4,  N=40, Completed, 
    Real-world data confirm that use of FIAsp in insulin pumps in paediatric populations improves glycaemic control long-term. Recruiting --> Completed | Trial completion date: Nov 2022 --> Mar 2023 | Trial primary completion date: Sep 2022 --> Dec 2022
  • ||||||||||  Journal:  Estimated Changes in Insulin Prices and Discounts After Entry of New Insulin Products, 2012-2019. (Pubmed Central) -  Jun 20, 2023   
    Net prices of short-acting insulin increased at an annual rate of 5.6% from 2012 to 2017 but then decreased from 2018 to 2019 after the introduction of insulin aspart (Fiasp) and lispro (Admelog)...In this longitudinal study of US insulin products, results suggest that insulin prices substantially increased from 2012 to 2015, even after accounting for discounts. The introduction of new insulin products was followed by substantial discounting practices that lowered net prices faced by payers.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion date, Trial primary completion date:  Evaluation of the MiniMed (clinicaltrials.gov) -  Jun 18, 2023   
    P=N/A,  N=250, Recruiting, 
    The introduction of new insulin products was followed by substantial discounting practices that lowered net prices faced by payers. Trial completion date: Nov 2023 --> Feb 2024 | Trial primary completion date: Aug 2023 --> Jan 2024
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Journal, Real-world evidence, Real-world, Metastases:  Real-World User and Clinician Perspective and Experience with MiniMed (Pubmed Central) -  Jun 6, 2023   
    The use of the AHCL system in T1DM resulted in robust glycemic control, minimizing hypoglycemia. Providing training to both users and HCPs can help them use the system effectively.
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Trial primary completion date, Combination therapy:  Afrezza (clinicaltrials.gov) -  May 8, 2023   
    P3,  N=264, Recruiting, 
    Clinical trials registration: NCT04759144. Trial primary completion date: Apr 2023 --> Aug 2023
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
    Trial completion date, Trial primary completion date:  Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) -  Apr 25, 2023   
    P3,  N=160, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: May 2023 --> Dec 2023 | Trial primary completion date: May 2023 --> Dec 2023